Eli Lilly and AC Immune (ACIU) are establishing a partnership to obtain a drug for the treatment of Alzheimer’s disease, worth up to $2 billion. Eli Lilly will pay ACIU an initial $80 million upfront, with more payments coming as certain milestones are met in the creation of the drug, which is currently only in pre-clinical stages of testing.
Eli Lilly continues its efforts despite having a significant setback in 2016, when it announced a phase 3 trial failure for its anti-amyloid drug, Solanezumab. Its new collaboration with ACIU comes as several pharmaceutical companies attempt to create treatments that can alleviate or completely cure Alzheimer’s disease. It is anticipated that the Alzheimer’s market will reach $14.8 billion by 2026.
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. AC Immune SA operates as a biopharmaceutical company. The Company discovers, designs, and develops medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
This was reported by Seeking Alpha on December 17, 2018.
Contact Information: Eli Lilly and Company Global Headquarters, Lilly Corporate Center, Indianapolis, Indiana 46285; (317) 276-2000; Website: www.lilly.com
Contact Information: AC Immune, EPFL Innovation Park, Building B, 1015 Lausanna, Switzerland: +41 21 345 91 21; Website: www.acimmune.com